Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 10, 2008

View Archived Issues

Mechanisms underlying antiarrhythmic effects of sodium tanshinone IIA sulfonate explored

Lundbeck reports preclinical pharmacology data on its novel treatment for mood disorders

New compounds for psychiatric disorders disclosed in recent patent literature

p38 MAP kinase inhibitor series optimization leads to UCB-1277763

Egis Pharmaceuticals presents EGIS-11148, a pyridazinone antipsychotic

Study confirms long-term efficacy of Sativex in MS neuropathic pain

CV Therapeutics initiates phase I CVT-3619 trial for cardiometabolic diseases

Alvesco inhalation aerosol available in U.S. for asthma

Five Prime initiates phase I FP-1039 trial in advanced solid tumors

Logical Therapeutics initiates double-blind, randomized study of LT-NS-001

Novel therapeutic options for HCV infection described in recent patents

Recent Merck and AstraZeneca patents report new agents for treating Alzheimer's disease

Anticancer dual VEGFR-2/3 and Flt3 kinase inhibitors active in preclinical models

Amgen develops selective CB2 agonists for analgesia

Peplin commences phase III PEP-005 gel trial in actinic keratoses

New recombinant Xyntha available for patients with hemophilia A

DSMB recommends continuation of Stem Cell's phase IIb REGENESIS trial of NTx-265

Elan and Biogen initiate treatment in phase I/II clinical trial of Tysabri in oncology

FDA grants fast track status to Celgene's amrubicin in small cell lung cancer

QuatRx initiates second phase III study of Ophena in postmenopausal vaginal syndrome

Procter & Gamble acquires NIOXIN Research Laboratories

MediciNova presents preliminary results from phase II MN-221 trial in asthma

Oncolytics Biotech enrolls patients in U.S. phase II Reolysin trial

Metabolic presents update on proposed acquisition of PolyNovo Biomaterials

Clinical studies of Akela's Taifun to be initiated in Finland and Japan